参考文献/References:
[1] Mach F,Baigent C,Catapano AL,et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J].Eur Heart J,2020,41(1):111-188.
[2] Sampson UK,Fazio S,Linton MF.Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins:the evidence,etiology,and therapeutic challenges[J].Curr Atheroscler Rep,2012,14(1):1-10.
[3] Tada H,Nohara A,Inazu A,et al.Remnant lipoproteins and atherosclerotic cardiovascular disease[J].Clin Chim Acta,2019,490:1-5.
[4] Sundaram M,Yao Z.Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion[J].Nutr Metab (Lond),2010,7:35.
[5] Sacks FM.The crucial roles of apolipoproteins E and C-Ⅲ in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia[J].Curr Opin Lipidol,2015,26(1):56-63.
[6] Sundvall J,Laatikainen T,Hakala S,et al.Systematic error of serum triglyceride measurements during three decades and the effect of fasting on serum triglycerides in population studies[J].Clin Chim Acta,2008,397(1-2):55-59.
[7] Langsted A,Freiberg JJ,Nordestgaard BG.Fasting and nonfasting lipid levels:influence of normal food intake on lipids,lipoproteins,apolipoproteins,and cardiovascular risk prediction[J].Circulation,2008,118(20):2047-2056.
[8] Sidhu D,Naugler C.Fasting time and lipid levels in a community-based population:a cross-sectional study[J].Arch Intern Med,2012,172(22):1707-1710.
[9] Iso H,Imano H,Yamagishi K,et al.Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women:the Circulatory Risk in Communities Study (CIRCS)[J].Atherosclerosis,2014,237(1):361-368.
[10] Egeland GM,Igland J,Sulo G,et al.Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol:Cohort Norway[J].Eur J Prev Cardiol,2015,22(7):872-881.
[11] Nordestgaard BG.A test in context:lipid profile,fasting?versus nonfasting[J].J Am Coll Cardiol,2017,70(13):1637-1646.
[12] Alberico L,Ian G,Guy DB,et al.2016 ESC EAS Guidelines for the management of dyslipidaemias[J].Eur Heart J,2016,37:2999-3058.
[13] 诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[14] Hegele RA,Ginsberg HN,Chapman MJ,et al.The polygenic nature of hypertriglyceridaemia:implications for definition,diagnosis,and management[J].Lancet Diabetes Endocrinol,2014,2(8):655-666.
[15] Patel A,Barzi F,Jamrozik K,et al.Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region[J].Circulation,2004,110(17):2678-2686.
[16] Sarwar N,Danesh J,Eiriksdottir G,et al.Triglycerides and the risk of coronary heart disease:10,158 incident cases among 262,525 participants in 29 Western prospective studies[J].Circulation,2007,115(4):450-458.
[17] Criqui MH,Heiss G,Cohn R,et al.Plasma triglyceride level and mortality from coronary heart disease[J].N Engl J Med,1993,328(17):1220-1225.
[18] Davey SG,Hemani G.Mendelian randomization:genetic anchors for causal inference in epidemiological studies[J].Hum Mol Genet,2014,23(R1):R89-R98.
[19] Mansouri RM,Baugé E,Gervois P,et al.Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia[J].Circ Res,2008,103(5):450-453.
[20] Ress C,Moschen AR,Sausgruber N,et al.The role of apolipoprotein A5 in non-alcoholic fatty liver disease[J].Gut,2011,60(7):985-991.
[21] Mar?ais C,Verges B,Charrière S,et al.Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment[J].J Clin Invest,2005,115(10):2862-2869.
[22] J?rgensen AB,Frikke-Schmidt R,West AS,et al.Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction[J].Eur Heart J,2013,34(24):1826-1833.
[23] Wang CS,McConathy WJ,Kloer HU,et al.Modulation of lipoprotein lipase activity by apolipoproteins.Effect of apolipoprotein C-Ⅲ[J].J Clin Invest,1985,75(2):384-390.
[24] J?rgensen AB,Frikke-Schmidt R,Nordestgaard BG,et al.Loss-of-function mutations in APOC3 and risk of ischemic vascular disease[J].N Engl J Med,2014,371(1):32-41.
[25] Crosby J,Peloso GM,Auer PL,et al.Loss-of-function mutations in APOC3,triglycerides,and coronary disease[J].N Engl J Med,2014,371(1):22-31.
[26] Nordestgaard BG,Varbo A.Triglycerides and cardiovascular disease[J].Lancet,2014,384(9943):626-635.
[27] Min J,Celine F,Jicheng L.Effects of fibrates on cardiovascular outcomes a systematic review and meta-analysis[J].Lancet,2010,375(9729):1875-1884.
[28] Skulas-Ray AC,PWF W,Harris WS,et al.Omega-3 fatty acids for the management of hypertriglyceridemia:a science advisory from the American Heart Association[J].Circulation,2019,140(12):e673-e691.
[29] McKenney JM,Sica D.Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia[J].Pharmacotherapy,2007,27(5):715-728.
[30] Manson JE,Cook NR,Lee IM,et al.Marine n-3 fatty acids and prevention of cardiovascular disease and cancer[J].N Engl J Med,2019,380(1):23-32.
[31] Bowman L,Mafham M,Wallendszus K,et al.Effects of n-3 fatty acid supplements in diabetes mellitus[J].N Engl J Med,2018,379(16):1540-1550.
[32] Bhatt DL,Steg PG,Miller M,et al.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J].N Engl J Med,2019,380(1):11-22.
[33] Nordestgaard BG,Zilversmit DB.Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits[J].J Lipid Res,1988,29(11):1491-1500.
[34] Chapman MJ,Ginsberg HN,Amarenco P,et al.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease:evidence and guidance for management[J].Eur Heart J,2011,32(11):1345-1361.
[35] Nordestgaard BG.Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease:new insights from epidemiology,genetics,and biology[J].Circ Res,2016,118(4):547-563.
[36] Nordestgaard BG,Langsted A,Mora S,et al.Fasting is not routinely required for determination of a lipid profile:clinical and laboratory implications including flagging at desirable concentration cutpoints-a joint consensus statement from the European Atherosclerosis Society and European federation of clinical chemistry and laboratory medicine[J].Clin Chem,2016,62(7):930-946.
[37] Norata GD,Grigore L,Raselli S,et al.Post-prandial endothelial dysfunction in hypertriglyceridemic subjects:molecular mechanisms and gene expression studies[J].Atherosclerosis,2007,193(2):321-327.
[38] Proctor SD,Vine DF,Mamo JC.Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis[J].Curr Opin Lipidol,2002,13(5):461-470.
[39] Borén J,Williams KJ.The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis:a triumph of simplicity[J].Curr Opin Lipidol,2016,27(5):473-483.
[40] 郭凯,周尊海.载脂蛋白B与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展.2018.39(6):877-880.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(10):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(10):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(10):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(10):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(10):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(10):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(10):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(10):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(10):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]